Efficacy and safety of botulinum toxin type A for postoperative scar prevention and wound healing improvement: A systematic review and meta-analysis.

Abstract

Botulinum toxin type A (BTXA) has shown underlying effects for wound healing improvement. New small clinical trials keep emerging every year and updated evidence-based information is warranted. This study aimed to evaluate the efficacy and safety of BTXA for preventing scarring. Four databases were searched to recruit randomized clinical trials (RCTs) which compared the surgical wounds treated with BTXA vs. those treated with placebo or blank control. The outcomes were primarily quantified by measures including the Vancouver Scar Scale (VSS), Visual Analog Scale (VAS), Stony Brook Scar Evaluation Scales (SBSES), modified SBSES (mSBSES), and scar width. Patients' satisfaction and adverse events were also reported. In total, 16 RCTs involving 671 cases (510 patients) were included. The outcome showed significant superiority of BTXA in VSS (mean difference [MD]=-1.32, 95% confidence interval [CI]: -2.00 to -0.65, p=0.0001), VAS (MD=1.29, 95% CI: 1.05-1.52, p<0.00001), SBSES or mSBSES (MD=-0.18, 95% CI: -0.27 to -0.10, p<0.0001), scar width (MD=-0.18, 95% CI: -0.27 to -0.10, p<0.0001), and patients' satisfaction (risk ratio [RR]=1.25, 95% CI: 1.06-1.49, p=0.01). No significant difference of adverse events incidence was observed (RR=1.46 95% CI: 0.64-3.33, p=0.36). Botulinum toxin type A is effective and safe for postoperative scar prevention and wound healing improvement, especially for facial wounds of Asians. Further studies should manage to standardize the treatment algorithm, while mSBSES is recommended for scar assessment.